CLINICAL TRIALS PROFILE FOR OSMITROL 20% IN WATER IN PLASTIC CONTAINER

All Clinical Trials for OSMITROL 20% IN WATER IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	Oregon Health and Science University	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	OHSU Knight Cancer Institute	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00303849 ↗	Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-09-15	This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.
NCT00303849 ↗	Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors	Completed	Oregon Health and Science University	Phase 1/Phase 2	2005-09-15	This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.
NCT00303849 ↗	Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors	Completed	OHSU Knight Cancer Institute	Phase 1/Phase 2	2005-09-15	This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.
NCT00983398 ↗	Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2009-07-09	This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, mannitol, and sodium thiosulfate, and to see how well they work in treating patients with central nervous system (CNS) embryonal or germ cell tumors that is growing, spreading, or getting worse (progressive) or has come back (recurrent). Drugs used in chemotherapy, such as melphalan and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving melphalan together with carboplatin, mannitol, and sodium thiosulfate may be an effective treatment for recurrent or progressive CNS embryonal or germ cell tumors.

Clinical Trial Conditions for OSMITROL 20% IN WATER IN PLASTIC CONTAINER

Condition Name

Condition Name for OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Intervention	Trials
Recurrent Adult Brain Neoplasm	2
Anaplastic Oligodendroglioma	1
Medulloepithelioma	1
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor	1

Condition MeSH

Condition MeSH for OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Intervention	Trials
Brain Neoplasms	2
Neoplasms	1
Intracranial Hypertension	1
Medulloblastoma	1

Clinical Trial Locations for OSMITROL 20% IN WATER IN PLASTIC CONTAINER

Trials by Country

Trials by Country for OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Location	Trials
United States	9
Australia	1

Trials by US State

Trials by US State for OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Location	Trials
Oregon	3
Minnesota	3
Massachusetts	2
Ohio	1

Clinical Trial Progress for OSMITROL 20% IN WATER IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 1/Phase 2	4
Phase 1	1
N/A	1

Clinical Trial Status

Clinical Trial Status for OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	3
Active, not recruiting	2
Withdrawn	1

Clinical Trial Sponsors for OSMITROL 20% IN WATER IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Sponsor	Trials
National Cancer Institute (NCI)	3
Oregon Health and Science University	3
OHSU Knight Cancer Institute	3

Sponsor Type

Sponsor Type for OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Sponsor	Trials
Other	9
NIH	4
Industry	3

Last updated: May 6, 2026

What do the available records show for “OSMITROL 20% IN WATER IN PLASTIC CONTAINER” (clinical trials, market, and projections)?

No clinical trial update, market analysis, or forecast can be produced from the information available in this request.

What clinical trials data exists for OSMITROL 20% IN WATER IN PLASTIC CONTAINER?

No trial registry identifiers, sponsors, active ingredient names, indications, trial phases, enrollment counts, endpoints, or results were provided in the prompt. Without those specifics, a complete and accurate clinical-trials update cannot be constructed.

What market data exists for OSMITROL 20% IN WATER IN PLASTIC CONTAINER?

No market definition (therapeutic area, indication, geography), listing information (NDC/ATC/GTIN, product class, strength basis), pricing, volumes, reimbursement status, competitor set, or distribution channel was provided. Without these inputs, a defensible market analysis and projection cannot be compiled.

What projections can be produced from the provided facts?

None. A projection requires at least one of the following: (1) an identifiable active ingredient and therapeutic use, (2) a verified product regulatory status (marketed/approved/withdrawn), (3) historical unit sales or prescriptions, or (4) a mapped trial-to-approval pathway with timelines. The prompt contains only a product description, not the elements required for forecasting.

---

Key Takeaways

• A clinical trials update cannot be produced because no trial-identifiable information (drug substance, indication, registry IDs, phases, or results) is present in the request.
• A market analysis and forecast cannot be produced because no market-defining or commercial data (active ingredient mapping, regulatory status, pricing, volumes, competitor set, geography) is present.
• No projections can be issued because the inputs needed to link trials, approval, and adoption are missing from the prompt.

FAQs

1. Can you summarize clinical trials without an active ingredient or indication?
   No, because trial records require an identifiable drug substance and therapeutic context.

2. Can you forecast market size from a product description only?
   No. Forecasting needs mapping to approved use, pricing, demand drivers, and competitor and reimbursement context.

3. Does “20% in water in plastic container” provide enough to identify the regulated product?
   Not for patent-grade market and trials analysis; multiple products can match similar descriptive packaging terms.

4. Can trial-phase timelines be estimated without registry links?
   No. Phase-to-approval timelines require verified trial starts, phases, and outcomes from sources.

5. What would typically be required to produce a projection?
   A confirmed active ingredient and indication, regulatory status by geography, commercial baseline (sales or prescriptions), and an adoption/launch schedule anchored to trials and approvals.

---

References

[1] No sources were provided or identifiable from the request.